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Iliac-caval stenting in the obese
Seshadri Raju, MD, Rikki Darcey, BS, and Peter Neglén, MD, PhD, Jackson, Miss
Background: Chronic venous insufficiency (CVI) in the obese, often with severe clinical manifestations, is increasingly
encountered in clinical practice. The association has drawn special interest as the pathophysiology may be different from
that seen in the non-obese. The disease poses special management problems in the obese as traditional conservative
measures are seldom effective. Iliac-caval venous stenting has been effective in CVI management but applicability in the
obese raises concerns regarding stent compression, morbidity and efficacy.
Methods: Results of iliac-caval stenting in 101 limbs of 87 patients are presented. Clinical features, venous test results, and
outcome after stenting are reported with comparison to select relevant features in the non-obese limbs (n  1513) that
were stented over the same 11 year period.
Results: Bilateral clinical manifestations CVI were twice as common in the obese subset compared with the non-obese
(28% vs 14% respectively, P .0007), the incidence increasing with BMI. Resting and exercise femoral vein pressures were
similar to the non-obese. Obstructive lesions of primary or postthrombotic origin similar to those seen in non-obese limbs
were detected by intravascular ultrasound examination in 89% of limbs. Compression by increased intra-abdominal
pressure associated with obesity was likely the mechanism of obstruction in 11% of the limbs. Iliac-caval venous stenting
was found to be safe with no mortality (<30 days), low morbidity (deep venous thrombosis in 3%), high patency (86%
cumulative at five years), and satisfactory clinical outcome. Sixty-eight percent and 46% of limbs showed cumulative
improvement in pain and swelling respectively at 5 1/2 years after stenting, with 65% and 31% limbs achieving complete
relief of these respective symptoms. Thirty of 45 limbs (58% cumulative) were free of dermatitis/ulcer at four years.
Conclusion: The mechanism of venous obstruction in the obese is substantially similar to those in the non-obese. Primary
or post-thrombotic lesions as seen in non-obese CVI cases are present in 89% of cases per IVUS examination.
Compression of the venous outflow by adiposity/abdominal pressure may be a factor in 11%. Iliac-caval venous stenting
is a satisfactory clinical option in the obese with severe CVI manifestations requiring speedy relief. ( J Vasc Surg 2009;50:
1114-20.)Chronic venous insufficiency (CVI) associated with
obesity is increasingly encountered in clinical practice.
Obesity associated increased abdominal pressure has been
implicated in the genesis of venous symptoms,1 and unique
calf pump abnormalities are present in this subset.2 CVI
manifestations in the obese pose special management chal-
lenges. Orthostatic limb pain and swelling retards exercise
and activity – essential components in weight reduction
programs. Body habitus, local skin condition, and limb
adiposity may prohibit or inhibit compression treatment as
stockings are difficult to fit, apply without assistance, and
maintain wear. Many obese patients cannot physically reach
their feet.3 Non-compliance with prescribed regimes, a
frequent factor in the onset of obesity, extends to compres-
sion use as well; non-compliance with compression is
widely prevalent even in ‘ulcer clinics’ under medical super-
vision.4 Ideally, a program of rigorous weight reduction
can be expected to reduce severity of CVI manifestations.
These programs are more often unsuccessful than not in
clinical experience, and generally do not accomplish satis-
factory weight reduction within a reasonable time frame
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1114relevant for the relief of severe venous symptoms. Bariatric
surgery, which has recently become minimally invasive and
safer than before, is a desirable option, but many patients
are unable (procedure not covered by many insurance
programs) or unwilling to avail themselves of this option.
Open surgical procedures to correct specific CVI pathology
carry higher risks than usual because of obesity and associ-
ated co-morbidities. The advent of minimally invasive tech-
niques such as percutaneous saphenous ablation provides
alternative and possibly safer therapeutic options. Iliac ve-
nous stenting also falls under this category of modern
treatment avenues but stent compression/occlusion by
intra-abdominal obesity and associated increased abdomi-
nal pressure5 along with the overall safety of these proce-
dures in this morbidity-prone subset are major concerns.
This manuscript describes the outcome of iliac vein stent
placement combined with saphenous ablation when indi-
cated in the obese. Venous parameters and other data
relevant to the increased abdominal pressure hypothesis in
the obese are also presented.
METHODS
A total of 1640 limbs underwent iliac-caval venous
stenting from 1997 to 2008 for severe symptoms of chronic
venous insufficiency. Of these, 101 limbs (6%) were per-
formed in 87 patients who were obese (World Health
Organization [WHO] classification)6 and had a Body Mass
Index (BMI) of 30. The current report is based on
analysis of this subset.
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and weight measurements routinely entered in venous lab-
oratory records. Obese severity was based on standard
classification6: Class 1 (BMI 30-35), Class II (BMI 36-40),
and Class III (BMI 40).
Relevant data was extracted from electronic medical
records that were contemporaneously entered and later
analyzed. For comparison purposes, the non-obese limbs in
the data set (n  1513) that were otherwise similar to the
obese group were used as controls for most parameters.
Because of missing data (test not performed because of
technical difficulty, no shows, or other reasons), n values for
comparisons vary, which are shown in context.
Indications for intravascular ultrasound
(IVUS)/venous stenting in the obese
Patients were selected based on persistent severity of
symptoms unresponsive to conservative measures: limb
pain, swelling, dermatitis/ulcer, or combination. Pain as-
sessment was based on visual analogue scale (0-10)7 and
swelling on venous severity scoring system (0, none; 1,
afternoon onset; 2, morning onset; 3, permanent).8
Preoperative investigations. A thrombophilia work-up
(Protein C&S, antithrombin 3, anticardiolipin antibody, lu-
pus anticoagulant, homocystine levels Factor V&10 gene
mutations) was routinely carried out. Other routine investiga-
tions included assessment in the venous laboratory duplex
examination, arm/foot pressure differential and reactive hy-
peremia pressure measurements,9 ambulatory venous pres-
sure measurement, airplethysmography, nucleotide lym-
phoscintography10 (in limbs with swelling for diagnostic
and prognostic value), and transfemoral venography with
exercise femoral pressure measurement as previously de-
scribed.11,12 An exercise pressure increase of 4 mm Hg
was considered significant. A resting pressure differential of
3mmHg over the contra lateral limb was also considered
significant. Many of the listed tests can be combined into
smaller number of procedures or performed from the same
venipuncture rendering the assessment process less onerous
than it appears. With some coordination in data collection,
investigative assessment is well tolerated. One or more of
these investigations were not possible in some patients
because of technical difficulties with venipuncture, large
limb size (air plethysmography [APG], pressure cuff), or
radiographic table weight limitations. A diagnostic intra-
vascular ultrasound examination (IVUS)13 was the defini-
tive test for iliac venous obstruction and carried out in all
symptomatic patients considered for stenting even if fore-
going tests were inconclusive or non-revealing of iliac vein
pathology. Venous stenting was carried out concurrently
with IVUS examination when a lesion was found.
IVUS allows area measurements of the venous lumen
by an electronic planimetry software that comes with the
device. Focal stenosis is calculated by comparing area of the
stenosis with normal area beyond the stenosis. Diffuse
stenosis, where the entire iliac vein segments are uniformly
narrowed, is approximated by comparing the luminal area
at the narrowest point to nominal maximal area expected in‘normal’ adults: 254 sq mm (based on 18 mm diameter,
which is often even larger in the obese) for the common
iliac vein.
Technique. The procedure was performed under gen-
eral anesthesia for better cardio-pulmonary and pain con-
trol in a dedicated endovascular suite in patients 450 lb
weight. A standard operating room table with C arm was
used for those exceeding the weight limit. Endovenous
ablation of the great saphenous vein was concurrently
carried out with the stent procedure if saphenous reflux was
present. IVUS examination was carried out via a mid-thigh
ante grade femoral vein access with the patient in the supine
position, which enhances procedural ease and anesthetic
safety in obese patients. Saphenous access (used for abla-
tion) for stent placement also is unsatisfactory because the
distal end of the stent may land in the upper spahenous vein
when infrainguinal stent extension is required, and the
common femoral vein segment below the saphenous entry
will be inaccessible to stent placement if needed. IVUS-
identified lesions were balloon dilated to normal adult
lumen size (16 mm-18 mm for common iliac, 14 mm-16
mm for external iliac, 12 mm-14 mm for common femoral
vein) and stented per standard technique.14 Recanalization
of totally occluded vein segments was carried out if needed
per technique previously described.15 Bilateral venous
stenting was staged with several weeks in between proce-
dures for technical ease and because contralateral symp-
toms often improve or abate following stenting of the most
symptomatic limb. When required, bilateral staged iliac
vein stenting requires fenestration of the initial stent; the
technique has been described in detail elsewhere.16 Large
caliber (16 mm-20 mm) braided stents (Wallstents; Boston
Scientific, Natick, Mass) were oversized by at least 2 mm
beyond balloon dilated size. This allows for potential over-
dilatation later in case of instent restenosis or stent com-
pression. Stents were routinely extended into the inferior
vena cava for 3 cm-5 cm to prevent recurrence of stenosis at
the iliac-caval junction. Stents were extended higher into
the infrarenal vena cava if caval disease was present. The
entire vein segment(s) (vena cava, common iliac, external
iliac, common femoral) bearing the IVUS-detected lesions
were covered in continuity with the stent assembly without
skip areas and with generous overlap (3 cm-5 cm) between
stents. Stents were extended across the inguinal ligament
into the common femoral vein if retroinguinal lesions/
compression were present or the common femoral vein was
itself involved in the disease process.
The same compression regimen (use or non-use) prac-
ticed by the patient preoperatively was continued after
stenting. Patients were maintained on aspirin 81 mg daily
on an empiric basis after stent placement unless thrombo-
philia was present or patients were already on anticoagula-
tion, in which cases warfarin anticoagulation was started/
continued. Patients were discharged after overnight stay.
Follow-up. Patients were clinically examined at six
weeks, three months, and at six-monthly intervals thereaf-
ter. Stent patency was routinely examined by transfemoral
venography at three to six months and yearly thereafter. In
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used at more frequent intervals for stent surveillance. The
duplex technique described by Labropoulos17 has been
found to be reliable in establishing stent patency (flow)
even in the obese population (unpublished data).
Data analysis
Continuous and categorical variables were analyzed by
paired non-parametric Wilcoxon-Rank test and Chi square
test, respectively. Primary, assisted-primary, and secondary
patency rates and clinical outcome were calculated using
survival analysis with the Kaplan-Meier method. Cumula-
tive survival analysis was used to compare clinical outcome
after stenting with present status. Survival curves were
pruned when standard error of the mean (SEM) exceeded
10%. A commercially available statistical program (Graph
Pad Prism for Windows [version 3.0; GraphPad Software
Inc, La Jolla, Calif]) was used for analysis. A P value of less
than .05 was considered significant.
RESULTS
Iliac-femoral venous stenting was performed in 87
obese patients (101 limbs, 14 bilateral); five patients re-
quired recanalization of an occlusion, one bilaterally. The
cephalad landing site of the stent assembly was in the distal
inferior vena cava in all limbs for the aforementioned tech-
nical reasons; in seven limbs a higher landing site below the
renal veins was chosen because of disease involvement of
the infrarenal vena cava. The distal landing site was in the
common iliac vein in 23 (23%) limbs and in the external
iliac vein in 21 (21%) limbs; in 57 limbs (56%) the stent was
extended below the inguinal ligament into the common
femoral vein. Concurrent percutaneous saphenous ablation
was performed in 22 limbs (20 laser, two radiofrequency).
Five additional limbs underwent traditional open stripping
concurrent with stenting.
The median weight was 273 lbs (range, 179 to 500
lbs [scale limit]), and BMI 42 (range, 30-83) (Fig 1).
Fig 1. Body mass index (BMI) distribution in 87 obese patients
who underwent iliac vein stenting for severe venous symptoms.Twenty-eight percent of patients were moderately obese(Class 1), 18% severely obese (Class II), and 54 % were
morbidly obese (Class III) per standard classification.6 Ex-
cept for higher BMI and increased incidence of bilateral
disease, the obese subset was similar to the non-obese
cohort in demographics, distribution across CEAP catego-
ries, and distribution of reflux. Median age was 49 years
(range, 23-84 years) versus 53 years in the non-obese,
Male/female ratio was 3:5 (2:5 in the non-obese). CEAP
classification of treated limbs is shown in Table I. The
incidence of dermatitis/ulcer was 46% (47/101 limbs) in
the entire obese subset versus 40% (602/1513 limbs) in the
non-obese (P .29, NS.), and 53% (29/55 limbs) in those
with BMI 40, (vs. 40% in non-obese, P  .07). Ratio of
primary and postthrombotic etiologies was 1.3:1, ratio of
obstruction alone vs obstruction with reflux 1:2, and ratio
of deep reflux alone vs combined superficial and deep reflux
1:1; these parameters were not different from those seen in
non-obese limbs (P  .68, 0.91, 0.90 respectively). Mean
multisegment reflux score was 1 (range, 0-6) in the obese
and also 1 (range, 0-7) in the non-obese (P  .85). Twen-
ty-eight of 101 (28%) obese patients had bilateral clinical
symptoms, significantly higher than 212/1513 (14%) in
the non-obese patients (P  .0007). The incidence of
bilateral disease was even higher, 21/55 (38%), in those
with a BMI 40 (P  .0001), significant compared with
the non-obese. Twenty-seven of 77 (35%) patients tested
had thrombophilia (37% in the non-obese): antithrombin
III (1), protein C (2), protein S (3), lupus anticoagulant
(3), prothombin gene (1), Leyden gene (2), homocysteine
gene (2), multiple (13). Sixty-two patients weremaintained
on aspirin and 25 on warfarin after the stent procedure.
Significant co-morbidities were present in many pa-
tients: non-insulin dependent diabetes in 7%; insulin de-
pendent diabetes in 6%; hypertension in 49%; sleep apnea in
6%; and history of congestive failure in 3%. Anesthetic risk
Table I. CEAP classification of 101 obese limbs
No. of limbs
Clinical classification
C2: varicose veins 3*
C3: edema 52
C4a: pigmentation or eczema 16
C4b: lipodermatosclerosis or white scar 7
C5: healed venous ulcer 7
C6: active venous ulcer 16
Etiologic classification
Ep: primary 57
Es: secondary 44
Anatomic classification
Ad: deep veins 51
As,d: superficial and deep veins 45
Ad,p: deep and perforator veins 1
As,d,p: superficial, deep, and perforator veins 4
Pathophysiologic
Po: obstruction 34
Pr,o: reflux and obstruction 67
*All had severe limb pain.categories (American Society of Anesthesiologists [ASA])
tients
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43%; Class 3: 52%; and Class 4: 4%.
Femoral vein pressures data was available in 73 obese
limbs and in 826 non-obese stented controls; comparison is
shown in Table II. Incidence of obstruction based on these
hemodynamic criteria was similar.
Nucleotide lymphoscintography showed normal drain-
age (15 minute node opacification) in 64 limbs, delayed
drainage (15-60 minutes node opacification) in four limbs,
and absent drainage (no node opacification at 60 minutes)
in one limb. Prevalence of lymphatic dysfunction (7%) was
significantly less than in the stented non-obese cohort (18%
or 173/964 limbs; P  .005).
IVUS area measurements. Varying degrees of steno-
sis were present in all patients who underwent IVUS exam-
ination; the stenosis was focal in 79 limbs (81%) and diffuse
in 19 limbs (19%) (data missing in three limbs). Among the
diffuse stenosis group (n  19), the etiology was judged
(prior thrombotic history and/or IVUS appearance) to be
postthrombotic (Rokitanski stenosis) in eight limbs and from
transmural compression in the abdominal compartment in 11
limbs, the latter representing 11% of the entire stented obese
subset. Mean area stenosis of focal lesions by IVUS measure-
ments was 74.9 % and diffuse lesions was 48.0%.
Patency. Cumulative secondary stent patency at five
years was 86%, as shown in Fig 2. Six stents occluded and
two were opened up with catheter-directed lysis.
Clinical outcome. Median (range) and mean (SD)
Fig 2. Cumulative patency of stents placed in limbs of obese
patients. Limbs at risk at each time interval are shown in the
bottom panel.
Table II. Femoral vein pressures in obese limbs compared
Femoral vein parameter
Resting pressure (45% tilt) Mm Hg median (range)
Pressure increase with exercise median (range)
Exercise pressure increase 4 mm Hg (% limbs)
% patients with bilateral 4 mm Hg pressure increase
Resting pressure differential 3 mm Hg over opposite limb (% pafollow up in the obese series were eight months (range,1-97 months) and 22 months (27), respectively. There
was no mortality (30 day). Deep venous thrombosis occurred
in three limbs (3%) involving the stent in one limb, below the
Fig 3. Cumulative relief of pain and swelling in limbs after stenting
in the obese. Partial relief of pain is defined as an improvement in pain
of at least 3/10 on visual analog scale (VAS) after stent placement.
Partial improvement in swelling is defined as an improvement of at
least one swelling grade on venous severity scoring system after stent
placement. Complete relief of pain or swelling indicates that no
residual pain or swelling was present after stent placement. The
cumulative curves were generated by censoring limbs that did not
meet the stated level of symptom thresholds at each time interval.
Limbs at risk at each time interval are shown in the bottom panel.
Fig 4. Cumulative freedom from dermatitis/ulcer in CEAP C
4-6 limbs after iliac vein stenting in the obese. Limbs at risk at each
time interval are shown in the bottom panel.
non-obese limbs
Obese limbs
N  73
Non-obese limbs
N  826 P value
24 (14-39) 24 (14-50) .85
3 mm Hg (0-26) 2.9 mm Hg (0-28) .48
34% 37% .84
28% 25% .16
) 17% 9% .13withstent in one limb, and in the contralateral limb in one.
right)
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cant pain relief (3/10 visual analog scale) at 5.5 years was
68%, with 65% of stented limbs achieving complete pain
relief as shown in Fig 3. Significant swelling improvement
( Gr. 1) occurred in 46% (cumulative) of limbs at 5.5
years after stenting with complete resolution of swelling in
42% (cumulative) of stented limbs (Fig 3). Fifty-eight
percent of limbs (cumulative) were free of ulcer/dermatitis
at four years, as shown in Fig 4; eight of 15 active ulcers
healed and remained healed at six years. A clinical example
is shown in Fig 5.
Venous function studies in the obese limbs before and
after stenting are shown in Table III; comparative data in
non-obese limbs are also shown. The limb venous volume
and ejection fraction measured by airplethysmography was
increased in the obese subset (prior to stenting) compared
with the non-obese. After stenting, venous volume normal-
ized. Subset analysis indicated that this change in venous
volume was entirely due to a substantial reduction in this
parameter (97 mL [range, 7-122 mL; n  16] to 64 mL
Fig 5. Obese patient with bilateral severe dermatitis, hy
months after staged bilateral iliac vein stent placement (
Table III. Hemodynamic parameters in obese and non-o
Test
Non-obese
Pre-stent N Pre-
AVP post-exercise pressure 68 (0-100) 1084 66 (26
VFT seconds 25 (0-248) 1073 24 (2-
APG VFI90 ml 1.9 (0-23) 1343 2.7 (0.
Venous volume (vv) 85 (5-388) 924 96 (29
Ejection fraction (EF) 50 (0-107) 923 59 (12
Residual volume fraction (RVF) 32 (0-146) 921 29 (2-
Hand/foot venous pressure
differential 1 (3-15) 948 1 (0-
Reactive hyperemia foot
pressure rise 5 (14-48) 995 6 (2-
APG VFI90 , Air plethysmography vein filling index; AVP, ambulatory veno
*Significant.[range, 33-110 mL; n  11]; P  .009) in obese patientswho underwent combined saphenous ablation with stent-
ing. No such changes were noted in venous volume (96mL
pre-stent [n 33] vs 101 mL post stent [n 23]; P 0.7
[NS]) in patients after stenting without saphenectomy.
Vein filling index (Vfi90) also decreased significantly (3.7
ml [range, 0.8-15.3 mL; n  24] to 1.8 mL [range,
0.4-12.2 mL; n  18]; P  .0025) after concurrent
saphenous ablation but was not reflected however in
aggregate in the entire obese subset. Higher ejection
fraction noticed in obese limbs was unrelated to co-
existing saphenous pathology and trended even higher
(not reaching statistical significance) after stent place-
ment; the increase was unrelated to saphenous ablation.
No other differences in functional testing from the non-
obese or after stenting were noted.
Reinterventions. There were 21 (21%) reinterven-
tions because of residual/recurrent symptoms. In 14
limbs, only balloon dilatation of the existing stent stack
was required. In seven others, the stent stack was ex-
tended cephalad in one, caudad in five, and in both
gmentation, and many small ulcers before (left) and five
.
limbs
Obese
Obese vs non-obese
pre-stent
Obese pre-stent
vs post-stent
N Post-stent N P P
68 68 (35-96) 18 .2924 .1099
67 21 (2-120) 19 .4928 .1929
3) 73 2 (0.5-4.2) 34 .0066* .7609
) 49 88 (33-185) 34 .0325* .0480*
) 49 67 (15-100) 34 .0437* .3084
49 28 (2-70) 34 .4016 .5998
55 0 (0-3) 18 .1137 .1934
45 4 (2-14) 15 .1848 .0625
ssure; VFP, venous filling time.perpibese
stent
-97)
117)
3-15.
-226
-118
88)
15)
23)
us predirections in one limb.
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It is not clear if there is a true increase in the incidence
of CVI because of obesity or if it merely reflects the increas-
ing obesity of the general population in association with a
common disease; epidemiological evidence is conflict-
ing.18-22 It has been reported that disease severity of CVI is
higher in the obese with bilateral manifestation and more
frequent incidence of dermatitis/ulcer than in the non-
obese.1-3 Painful lipedema is a distinct clinical feature in the
obese (Fig 6). Severe skin changes are often circumferential
in extent (Fig 7). In the current report, increased incidence
of bilateral disease was noticed in the obese subset, but
evidence for increased clinical and functional severity was
mixed. There was a trend towards greater clinical severity in
those with a BMI 40 but a significant association in the
entire obese subset was not present. Pathophysiologic
mechanisms contributing to CVI may also be different in
the obese. Hypotheses of such non-traditional mechanisms
include genetic predisposition,1 cytokine activation associ-
ated with obesity that damages microcirculation,23-25 lym-
phatic dysfunction,3,26,27 and increased intra-abdominal
pressure.1-3,23,28,29 In the current series, incidence of lym-
phatic dysfunction using standard nucleotide technique
was actually less than in the non-obese subset and less than
generally reported by others in CVI patients.30,31 More
sophisticated lymph transport tests showing a link between
obesity and lymphatic dysfunction26 were not carried out in
this series. There is solid evidence that intra abdominal
pressure is increased in the obese, which may be reflected in
increased femoral vein pressures as reported by others.1,23
Peripheral venous pressure may also be increased.2 There is
dilatation of the femoral vein with increased severity of
reflux though calf muscle pump may be paradoxically in-
creased attributable to bigger calf muscle mass in the obese;
lack of activity may, however, nullify this advantage.2 In the
current study, ejection fraction was shown to be abnormally
high in the obese; after stenting there was a trend in further
Fig 6. Painful lipedema in obese patient. Pain was completely
relieved after iliac vein stenting.improvement in ejection fraction. However, resting andexercise femoral pressures were similar to the non-obese in
the current analysis. Vfi90 did improve and venous volume
normalized because of concurrent saphenous ablation. The
mechanistic connection between obesity and venous symp-
toms is particularly intriguing in patients who have severe
venous manifestations without detectable duplex reflux. In
a report by Padberg and associates,3 nearly two thirds of
patients fell into this category, leading the authors to sug-
gest that compression of venous outflow by increased ab-
dominal pressure was likely the basis of the venous mani-
festations. In the obese subset presented herein, the
incidence and distribution of reflux was similar but all were
found to have iliac vein outflow obstruction on IVUS
examination. Focal or diffuse primary or postthrombotic
lesions of the traditional variety were identified in all but 11
(11%) limbs. Obesity related compressive mechanism was
thought to be the operative mechanism in the latter small
group. This finding does not necessarily contradict the
increased intra abdominal pressure theory as higher trans-
mural pressure can further amplify existing organic obstruc-
tive lesions. We have previously shown that venography
even by the transfemoral route is insensitive to iliac vein
assessment.11 IVUS is the preferred diagnostic tool for this
purpose; IVUS-detectable lesions are present in 90% of
patients with advanced CVI features (CEAP clinical class 3
or greater).11,32
Weight reduction surgery improves venous symp-
Fig 7. Obese patient with ‘inverted bottle’ leg. Lipodermatoscle-
rosis and scarring has constricted the lower leg with the upper leg
remaining large. Severe dermatitis with ulcerations is present cir-
cumferentially around the limb.toms,28 and is the ideal first choice to address comprehen-
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ifestations associated with obesity. The severity of venous
symptoms such as pain, recurrent cellulitis, or the exten-
siveness of skin breakdown in some patients may dictate
immediate attention to this problem before considering a
slower systemic solution. Iliac venous stenting appears to
offer specific relief for such patients with high degree of
long term patency, low morbidity, and satisfactory efficacy.
The procedure is conveniently combined with percutane-
ous saphenous ablation with negligible additional morbid-
ity when indicated.33 While saphenous reflux is a factor in
CVI manifestations and may be associated with medial
ulcers, saphenous ablation alone is unlikely to relieve the
circumferential dermatitis/ulcerations, extensive swelling,
and pain that are common in the obese patient. A combined
saphenous ablation/vein stent placement in a single stage
when saphenous reflux is present is therefore preferred in
this subset over an incremental approach to maximize
outcome at the outset andminimize the need for additional
future procedures with attendant additive risks.
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